載入中
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
前收盤價
US$9.46
+US$0.17 · +1.83%
盤前
US$9.40
−US$0.06 · -0.63%
10月12日 上午8:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
日內區間
目前US$9.46
52週區間
目前US$9.46
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1625.86萬 USD | 1129.27萬 USD | 873.5萬 USD | 419.58萬 USD | 12.65萬 USD |
| 銷售、一般及管理費用 | 1369.78萬 USD | 1138.2萬 USD | 740.61萬 USD | 402.32萬 USD | 122.55萬 USD |
| 營業費用 | 2995.64萬 USD | 2267.47萬 USD | 1614.11萬 USD | 821.89萬 USD | 135.2萬 USD |
| 利息收入 | 55.55萬 USD | 101.74萬 USD | 57.2萬 USD | — | — |
| 利息支出 | — | — | — | 497 USD | 17.99萬 USD |
| 折舊和攤銷 | 36.45萬 USD | 11.54萬 USD | 5468 USD | 2135 USD | 2468 USD |
| 營業利益 | −2995.64萬 USD | −2267.47萬 USD | −1614.11萬 USD | −821.89萬 USD | −135.2萬 USD |
| 淨利 | −2943.86萬 USD | −2161.34萬 USD | −1542.6萬 USD | −822.97萬 USD | −2438.39萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$23.33
上漲空間 146.62%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2498.03萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1937.2萬0.20%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1458.01萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF966.72萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO510.48萬0.04%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO331.27萬0.02%180億 USD0.06%US$112.66+0.50%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS241.84萬0.61%3.99億 USD0.60%US$107.24+1.40%
iShares Micro-Cap ETFIWC174.82萬0.13%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
